What is ANNX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.76B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ANNX?

P/E (TTM) is n/a and 52-week range is $2.54 to $7.18 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ANNX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ANNX?

The company profile lists net income (TTM) near $-188M, EPS (TTM) near $-1.15 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Annexon Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Brisbane California, California, US, 163.8M shares outstanding, ISIN US03589W1027 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Annexon Inc

$ANNX

Health Care · Biotechnology

IR Run Scenarios

$4.02

+0.50%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 96 full-time employees. The company went IPO on 2020-07-24. The company identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). The company is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. The company is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Employees

Website

annexonbio.com/

IPO

2020-07-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)